Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ALK status confers therapeutic sensitivity to Crizotinib in patients with Inflammatory Myofibroblastic Tumor.
The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumor (IMT).
This statement is based on a regulatory approval from the European Medicines Agency:
XALKORI as monotherapy is indicated for the treatment of paediatric patients (age >= 1 to <18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumour (IMT).